Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026)

Galectin Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $686000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 46.58% year-over-year to $686000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 13.89% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 32.33% from the prior year.
• Share-based Compensation advanced to $686000.0 in Q1 2026 per GALT's latest filing, from $88579.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.0 million in Q2 2025 and bottomed at $72000.0 in Q1 2024.
• The 5-year median for Share-based Compensation is $515000.0 (2024), against an average of $479257.0.
• Across the five-year window, Share-based Compensation plunged 86.95% in 2023 and jumped 550.0% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $178000.0 in 2022, then slipped by 12.17% to $156345.0 in 2023, then jumped by 92.17% to $300445.0 in 2024, then plunged by 70.52% to $88579.0 in 2025, then surged by 674.45% to $686000.0 in 2026.
• Per Business Quant, the three latest GALT Share-based Compensation figures stand at $686000.0 (Q1 2026), $88579.0 (Q4 2025), and $498000.0 (Q3 2025).